Saputra Taufik, Sutiyono Doso, Istanto Nurcahyo Widya
Faculty of Medicine, Diponegoro University, Semarang, Indonesia.
Department of Anesthesiology and Intensive Care, Dr. Kariadi General Hospital, Faculty of Medicine, Diponegoro University, Semarang, Indonesia.
Anesth Pain Med. 2024 Oct 8;14(5):e150753. doi: 10.5812/aapm-150753. eCollection 2024 Oct.
The rhomboid intercostal block (RIB) is an emerging regional anesthesia (RA) technique used for pain control following thoracic and breast surgery. However, comprehensive documentation on its effectiveness and safety profile remains limited. This study aims to assess the effectiveness and safety of RIB in thoracic and breast surgical procedures.
A study search was conducted following PRISMA 2020 guidelines in PubMed, Cochrane Library, Embase, Scopus, and ProQuest from 2016 to 2023 to identify randomized controlled trials (RCTs) evaluating the effectiveness and safety of RIB in thoracic and breast surgeries. The primary outcome was patient pain scores at rest, recorded at one, six, 12, and 24 hours post-surgery. Secondary outcomes included 24-hour opioid consumption and rates of postoperative nausea and vomiting (PONV).
This meta-analysis included five RCTs with a total of 368 patients. Rhomboid intercostal block led to a significant reduction in NRS scores one hour post-surgery (SMD = -1.33; 95% CI = -1.74 to -0.91; P < 0.00001, I² = 18%, P = 0.27), 12 hours post-surgery (SMD = -0.74; 95% CI = -0.99 to -0.48; P < 0.00001, I² = 36%, P = 0.21), and 24 hours post-surgery (SMD = -1.62; 95% CI = -2.56 to -0.69; P = 0.0006, I² = 91%, P < 0.00001). Regarding secondary outcomes, the RIB group showed a significant reduction in 24-hour opioid consumption (SMD = -4.49; 95% CI = -6.09 to -2.90; P < 0.00001, I² = 95%, P < 0.00001) and PONV rates (RR = 0.29; 95% CI = 0.18 to 0.47; P < 0.00001, I² = 0%, P = 0.88).
Rhomboid intercostal block provides effective pain reduction and lowers opioid consumption within 24 hours post-surgery, while also minimizing PONV rates.
菱形肌间沟阻滞(RIB)是一种新兴的区域麻醉(RA)技术,用于胸部和乳腺手术后的疼痛控制。然而,关于其有效性和安全性的全面文献仍然有限。本研究旨在评估RIB在胸部和乳腺手术中的有效性和安全性。
按照PRISMA 2020指南,于2016年至2023年在PubMed、Cochrane图书馆、Embase、Scopus和ProQuest中进行研究检索,以识别评估RIB在胸部和乳腺手术中有效性和安全性的随机对照试验(RCT)。主要结局是术后1小时、6小时、12小时和24小时记录的患者静息时疼痛评分。次要结局包括24小时阿片类药物消耗量以及术后恶心呕吐(PONV)发生率。
该荟萃分析纳入了5项RCT,共368例患者。菱形肌间沟阻滞导致术后1小时NRS评分显著降低(标准化均数差[SMD]=-1.33;95%可信区间[CI]=-1.74至-0.91;P<0.00001,I²=18%,P=0.27),术后12小时(SMD=-0.74;95%CI=-0.99至-0.48;P<0.00001,I²=36%,P=0.21),以及术后24小时(SMD=-1.62;95%CI=-2.56至-0.69;P=0.0006,I²=91%,P<0.00001)。关于次要结局,RIB组24小时阿片类药物消耗量显著降低(SMD=-4.49;95%CI=-6.09至-2.90;P<0.00001,I²=95%,P<0.00001),PONV发生率也显著降低(相对危险度[RR]=0.29;95%CI=0.18至0.47;P<0.00001,I²=0%,P=0.88)。
菱形肌间沟阻滞在术后24小时内可有效减轻疼痛、降低阿片类药物消耗量,同时还能将PONV发生率降至最低。